Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report); 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed February 4, 2021.
   Google Scholar
• Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breath. 2014;10(2):111–120. doi:10.1183/20734735.014813
   Google Scholar
• Shirtcliffe P, Weatherall M, Marsh S, et al. COPD prevalence in a random population survey: a matter of definition. Eur Respir J. 2007;30(2):232–239. doi:10.1183/09031936.00157906
   PubMed Web of Science ®Google Scholar
• Barnard L, Zhang J. The impact of respiratory disease in New Zealand: 2018 update. Asthma + Respiratory Foundation NZ; 2019.
   Google Scholar
• Yang IA, Brown JL, George J, et al. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease; 2020. Available from: https://copdx.org.au/copd-x-plan/Last. Accessed February 4, 2021.
   Google Scholar
• Pharmaceutical Management Agency (PHARMAC). Medicine targeting: how do we target medicines? Available from: https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/from-application-to-funded-medicine-how-we-fund-a-medicine/medicine-targeting/. Accessed April 1, 2021.
   Google Scholar
• Best Practice Advocacy Centre New Zealand (BPACnz). Newly-subsidised medicines for the treatment of patients with COPD. Best Pract J. 2016;74:7–13.
   Google Scholar
• Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012;129(3 Suppl):S34–48. doi:10.1016/j.jaci.2011.12.983
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease (2017 report). GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Ministry of Health – Manatū Hauora (New Zealand Government). Enrolment in a primary health organisation; 2020. Available from: https://www.health.govt.nz/our-work/primary-health-care/about-primary-health-organisations/enrolment-primary-health-organisation. Accessed April 1, 2021.
   Google Scholar
• HealthStat Primary Health Care Intelligence. HealthStat general practice database. http://www.healthstat.co.nz/Login.aspx?ReturnUrl=%2fdefault.aspx. Accessed April 1, 2021.
   Google Scholar
• Bogart M, Stanford RH, Laliberte F, et al. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. doi:10.2147/COPD.S184653
   PubMed Web of Science ®Google Scholar
• Palli SR, Frazer M, DuCharme M, et al. Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy. J Manag Care Spec Pharm. 2020;26(10):1363–1374. doi:10.18553/jmcp.2020.2015
   PubMed Web of Science ®Google Scholar
• Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respir Res. 2018;19(1):172. doi:10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92–100. doi:10.4104/pcrj.2012.00092
   PubMedGoogle Scholar
• Parkin L, Barson D, Zeng J, et al. Patterns of use of long-acting bronchodilators in patients with COPD: a nationwide follow-up study of new users in New Zealand. Respirology. 2018;23(6):583–592. doi:10.1111/resp.13235
   PubMed Web of Science ®Google Scholar
• Lim R, Kerr M, Roughead EE. Use of medicines and health services for chronic obstructive pulmonary disease among a cohort of Australians over 50 years. Int J Chron Obstruct Pulmon Dis. 2018;13:3085–3093. doi:10.2147/COPD.S172495
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2020 report); 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed April 1, 2021.
   Google Scholar
• Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi SM, et al. Identification and definition of asthma-COPD overlap: the CanCOLD study. Respirology. 2020;25(8):836–849. doi:10.1111/resp.13780
   PubMed Web of Science ®Google Scholar
• Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12(1):127. doi:10.1186/1465-9921-12-127
   PubMedGoogle Scholar
• Menezes AMB, Montes de Oca M, Pérez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297–304. doi:10.1378/chest.13-0622
   PubMed Web of Science ®Google Scholar
• Landis SH, Wurst K, Le HV, et al. Can assessment of disease burden prior to changes in initial COPD maintenance treatment provide insight into remaining unmet needs? A retrospective database study in UK primary care. COPD. 2017;14(1):80–85. doi:10.1080/15412555.2016.1240159
   PubMedGoogle Scholar
• Santus P, Centanni S, Verga M, et al. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med. 2006;100(7):1277–1281. doi:10.1016/j.rmed.2005.10.008
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Adherence to long-term therapies: evidence for action; 2003. Available from: https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1. Accessed April 1, 2021.
   Google Scholar
• Haynes RB, McDonald H, Garg AX, et al.Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;(2):Cd000011. doi:10.1002/14651858.CD000011
   PubMedGoogle Scholar
• Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371–384. doi:10.2147/COPD.S3036
   PubMedGoogle Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–943. doi:10.1136/thx.2009.113662
   PubMed Web of Science ®Google Scholar
• Best Practice Advocacy Centre New Zealand (BPACnz). Diagnosis and management of COPD in Māori and Pacific peoples. Best Pract J. 2012;43:14–25.
   Google Scholar
• Milne RJ, Beasley R. Hospital admissions for chronic obstructive pulmonary disease in New Zealand. N Z Med J. 2015;128(1408):23–35.
   PubMed Web of Science ®Google Scholar
• Dummer J, Tumilty E, Hannah D, et al. Health care utilisation and health needs of people with severe COPD in the southern region of New Zealand: a retrospective case note review. COPD. 2020;17(2):136–142. doi:10.1080/15412555.2020.1724275
   PubMedGoogle Scholar
• Stats NZ Tatauranga Aotearoa (New Zealand Government). New Zealand’s population reflects growing diversity. Ethnicity as a proportion of the population; 2019. Available from: https://www.stats.govt.nz/news/new-zealands-population-reflects-growing-diversity. Accessed August 1, 2020.
   Google Scholar